Improving public health through access to and utilization of medication assisted treatment

International Journal of Environmental Research and Public Health

Volumn 8, Issue 10, 2011, Pages 4102-4117

  Kresina, Thomas F ^a   Lubran, Robert ^a  

^a SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

Infectious diseases; Medical care; Medication assisted treatment; Opioid abuse; Opioid dependence; Recovery

Indexed keywords

BUPRENORPHINE; CLONIDINE; METHADONE; NALTREXONE; PLACEBO;

DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICATION ASSISTED TREATMENT; MORTALITY; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; PUBLIC HEALTH SERVICE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SOCIAL BEHAVIOR; TUBERCULOSIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80055065479     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph8104102     Document Type: Review

References (74)

1. Jan, S.A. Introduction: Landscape of opioid dependence. J. Manag. Care Pharm. 2010, 16, S4-S8.
2. United Nations Office of Drugs Control (UNODC). World Drug Report 2009; United Nations Publications: New York, NY, USA, 2009; pp. 42-51. Available online: http://www.unodc.org/documents/wdr/WDR_2009/WDR2009_eng_web.pdf (accessed on 8 October 2011).
3. Carinci, A.J.; Mao, J. Pain and opioid addiction: What is the connection? Curr. Pain. Headache Rep. 2010, 14, 17-21.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; American Psychiatric Association: Washington, DC, USA, 1994; pp. 176-183.
5. Stockman, J.K.; Strathdee, S.A. HIV among people who use drugs: A global perspective of populations at risk. J. Acquir. Defic. Immune Syndr. 2010, 55, S17-S26.
6. Freidland, G. Infectious disease comorbidities adversely affecting substance users with HIV: Hepatitis C and tuberculosis. J. Acquir. Defic. Immune Syndr. 2010, 55, S37-S42.
7. New York State Department of Health, AIDS Institute. Substance Use in Patients with HIV/AIDS. HIV Clinical Guidelines for the primary care Practitioner, 2009. Available online: www.hivguidelines.org (accessed on 8 October 2011).
8. National Institute on Drug Abuse (NIDA). Principles of Drug Addiction Treatment. A Research-Based Guide; NIH Publication No. 00-4180. National Institutes of Health: Bethesda, MD, USA, 2000.
9. Substance Abuse and Mental Health Services Administration (SAMHSA). Medication-assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) 43; Department of Health and Human Services Publication No. 05-4048. SAMHSA: Rockville, MD, USA, 2005. Available online: http://www.ncbi.nlm.nih.gov/books/NBK14677/ (accessed on 8 October 2011). Errata available at: http://www.kap.samhsa.gov/products/manuals/tips/pdf/tip43_erratum_10_08.pdf.
10. Metzger, D.S.; Woody, G.E.; O'Brian, C.P. Drug treatment as HIV prevention: A research update. J. Acquir. Defic. Immune Syndr. 2010, 55, S32-S36.
11. Sibthorpe, B.; Drinkwater, J.; Gardner, K.; Bammer, G. Drug use, binge drinking and attempted suicide among homeless and potentially homeless youth. Aust. N. Z. J. Psychiatry 1995, 29, 258-256.
12. Kirby, L.G.; Zeeb, F.D.; Winstanley, C.A. Contributions of serotonin in addiction vulnerability. Neuropharmacology 2011, 61, 421-432.
13. Sihvola, E.; Rose, R.J.; Dick, D.M.; Korhonen, T.; Pulkkinen, L.; Raevuori, A.; Marttunen, M.; Kaprio, J. Prospective relationships of ADHD symptoms with developing substance use in a population-derived sample. Psychol. Med. 2011, 20, 1-9.
14. Jenkins, M.B.; Agrawal, A.; Lynskey, M.T.; Nelson, E.C.; Madden, P.A.; Bucholz, K.K.; Heath, A.C. Correlates of alcohol abuse/dependence in early-onset alcohol-abusing women. Am. J. Addict. 2011, 20, 429-434.
15. Neaigus, A.; Miller, M.; Freidman, S.R.; Hagen, D.L.; Sifaneck, S.J.; Ildefonso, G.; Des Jarlais, D.C. Potential risk factors for the transition to injecting among non-injecting heroin users: A comparison of former injectors and never injector. Addiction 2001, 96, 847-860.
16. Roy, E.; Haley, N.; Leclerc, P.; Cedras, L.; Blais, L.; Boivin, J.F. Drug injection among street youths in Montreal: predictors of initiation. J. Urban Health 2003, 80, 92-105.
17. Valdez, A.; Neaigus, A.; Kaplan, C.; Cepeda, A. High rates of transitions to injecting drug use among Mexican American non-injecting heroin users in San Antonio, Texas (never and former injectors). Drug Alcohol Depend. 2011, 114, 233-236.
18. Neaogus, A.; Gyarmathy, A.; Miller, M.; Frajzyngier, V.M.; Friedman, S.R.; Des Jarlais, D.C. Transitions to injecting drug use among noninjecting heroin users. Social network influence and individual susceptibility. J. Acquir. Immune. Defic. Syndr. 2006, 41, 493-503.
19. Kresina, T.F.; Sylvestre, D.L.; Seeff, L.; Litwin, A.H.; Buffington, J.; Leavitt, S.B.; Hoffman, K.; Lubran, R.; Clark, H.W. Hepatitis infection in the treatment of opioid dependence and abuse. Subst. Abuse Res. Treat. 2008, 1, 15-61.
20. Zubaran, C.; Foresti, K. Quality of life and substance use: Concepts and related tendencies. Curr. Opin. Psychiatry 2009, 22, 281-286.
21. World Health Organization, Regional Office for South-East Asia. Management of Common Health Problems of Drug Users; World Health Organization, Regional Office for South-East Asia: New Delhi, India, 2009. Available online: http://www.searo.who.int/LinkFiles/HIV-AIDS_Primary_care_guidelines.pdf (accessed on 8 October 2011).
22. Arendt, M.; Munk-Jorgensen, P.; Sher, L.; Jensen, S.O.W. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA and opioid use disorders: a nationwide follow-up of Danish substance users in treatment. Drug Alcohol Depend. 2011, 114, 134-139.
23. Miller, C.L.; Strathdee, S.A.; Li, K.; Kerr, T.; Wood, E. A longitudinal investigation into excess risk for blood-borne infection among young injection drug users (IUDs). Am. J. Drug Alcohol Abuse 2007, 33, 527-536.
24. Bruce, R.D.; Altice, F.L. Clinical care of the HIV-infected drug user. Infect. Dis. Clin. North Am. 2007, 21, 149-179.
25. Cavanaugh, C.E.; Latimer, W.W. Recent sex trade and injection drug use among pregnant opiate and cocaine dependent women in treatment: The significance of psychiatric comorbidity. Addict. Disord. Their Treat. 2010, 9, 32-40.
26. Strathdee, S.A.; Stockman, J.K. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr. HIV/AIDS Rep. 2010, 7, 99-106.
27. Havens, J.R.; Oser, C.B.; Knudsen, H.K.; Lofwall, M.; Stoops, W.W.; Walsh, S.L.; Leukefeld, C.G.; Kral, A.H. Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend. 2011, 115, 107-112.
28. Des Jarlais, D.C.; Arasteh, K.; Perlis, T. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007, 21, 231-235.
29. Meade, C.S.; McDonald, L.J.; Weiss, R.D. HIV risk behavior in opioid dependent adults seeking detoxification treatment: An exploratory comparison of heroin and oxycodone users. Am. J. Addict. 2009, 18, 289-293.
30. Wu, L.T.; Woody, G.E.; Yang, C.; Blazer, D.G. How do prescription opioid users differ from users of heroin or other rugs in psychopathology: Results from the National Epidemiological Survey on Alcohol and Related Conditions. J. Addict. Med. 2011, 5, 28-35.
31. Abuse and Mental Health Services Administration (SAMHSA). Guidelines for the Accreditation of Opioid Treatment Programs; SAMHSA: Rockville, MD, USA, 2007. Available online: http://www.dpt.samhsa.gov/pdf/OTPAccredGuidelines-2007.pdf (accessed on 8 October 2011).
32. Kreek, M.J.; Borg, L.; Ducat, E.; Ray, B. Pharmacotherapy in the treatment of addiction: Methadone. J. Addict. Dis. 2010, 29, 200-216.
33. Banta-Green, C.J.; Maynard, C.; Koepsell, T.D.; Wells, E.A.; Donovan, D.M. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction 2009, 104, 775-783.
34. Substance Abuse and Mental Health Services Administration (SAMHSA). Medication Assisted Treatment for Opioid Addiction, 2010 State Profiles; SAMHSA: Rockville, MD, USA, 2010.
35. Substance Abuse and Mental Health Services Administration (SAMHSA). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) 40; DHHS Publication No. 04-3939. SAMHSA: Rockville, MD, USA, 2004. Available online: http://www.dpt.samhsa.gov/reports/index.htm (accessed on 8 October 2011).
36. Mendelson, J.M.; Flower, K.; Pletcher, M.J. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine. Exp. Clin. Psychopharmacol. 2008, 16, 435-441.
37. Fiellin, D.A.; O'Connor, P.G. Clinical practice. Office-based treatment of opioid-dependent patients. N. Engl. J. Med. 2002, 347, 817-823.
38. Cheever, L.W.; Kresina, T.F.; Cajina, A.; Lubran, R. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care. J. Acquir. Immune Defic. Syndr. 2011, 56, S3-S6.
39. Greenstein, R.A.; Evans, B.D.; McLellan, A.T.; O'Brien, C.P. Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend. 1983, 12, 173-180.
40. Krupitsky, E.; Zvartau, E.; Woody, G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr. Psychiatry Rep. 2010, 12, 448-453.
41. Krupitsky, E.M.; Blokhina, E.A. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr. Opin. Psychiatry 2010, 23, 210-214.
42. Kresina, T.F.; Litwin, A.; Marion, I.; Lubran, R.; Clark, H.W. Federal government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. Journal of Drug Policy Analysis 2009, 2, 1-23.
43. Code of Federal Regulations. Title 42: Public Health, Chapter 1: Public Health Service, Department of Health and Human Services, Part 8: Certification of Opioid Treatment Programs. Government of United States: Washington, DC, USA, 2002. Available online: http://www.access.gpo.gov/nara/cfr/waisidx_02/42cfr8_02.html (accessed on 8 October 2011).
44. Substance Abuse and Mental Health Services Administration (SAMHSA). 2005 SAMHSA Evaluation of the Impact of the DATA Waiver Program; SAMHSA: Rockville, MD, USA, 2005. Available online: http://buprenorphine.samhsa.gov/evaluation.html (accessed on 8 October 2011).
45. National Institutes of Health. Effective medical treatment of opiate addiction. NIH Consens. Statement 1997, 15, 1-38.
46. Hubbard, R.L.; Craddock, S.G.; Anderson, J. Overview of 5-year follow-up outcomes in the drug abuse treatment outcome studies (DATOS). J. Subst. Abuse Treat. 2003, 25, 125-134.
47. Kleber, H.D. Methadone maintenance 4 decades later: Thousands of lives saved but still controversial. JAMA 2008, 300, 2303-2305.
48. Nyamathi, A.; Smith, D.M.; Shoptaw, S.; Mutere, M.; Cohen, A.; Amrani, I.; Morales, L.; de Castro, V. Perceptions of methadone maintained clients about barriers and facilitators to help-seeking behavior. Progress in Community Health Partnerships: Research, Education, and Action 2007, 1, 301-309.
49. Substance Abuse and Mental Health Services Administration (SAMHSA). Providing a Continuum of Care: Improving Collaboration Among Services; SAMHSA: Rockville, MD, USA, 2009. Available online: http://store.samhsa.gov/product/SMA09-4388 (accessed on 8 October 2011).
50. Collins, C.; Hewson, D.L.; Munger, R.; Wade, T. Evolving Models of Behavioral Health Integration in Primary Care. Milbank Memorial Fund Report: New York, NY, USA, 2010. Available online: http://www.milbank.org/reports/10430EvolvingCare/EvolvingCare.pdf (accessed on 8 October 2011).
51. Freidmann, P.D.; Alexander, J.A.; Jin, L.; D'Aunno, T.A. On-site primary care and mental health services in outpatient drug abuse treatment units. J. Behav. Health Serv. Res. 1999, 26, 80-94.
52. Kresina, T.F.; Bruce, R.D.; Lubran, R.; Clark, H.W. Integration of viral hepatitis services into opioid treatment programs. J. Opioid. Manag. 2008, 4, 369-381.
53. Altarac, D.; Dansky, S.F. Tuberculosis treatment through directly observed therapy in a large multisite methadone maintenance treatment program: addressing the public health needs of a high risk population. J. Public Health Manag. Pract. 1995, 1, 40-47.
54. Gunderson, E.W.; Fiellin, D.A. Office-based maintenance treatment of opioid dependence: How does it compare with traditional approaches? CNS Drugs 2008, 22, 99-111.
55. Sullivan, L.E.; Bruce, R.D.; Haltiwanger, D.; Lucas, G.M.; Eldred, L.; Finkelstein, R.; Fiellin, D.A. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin. Infect. Dis. 2006, 43, S191-S196.
56. Schackman, B.R.; Merrill, J.O.; McCarty, D.; Levi, J.; Lubinski, C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin. Infect. Dis. 2006, 43, S247-S253.
57. Moore, B.A.; Fiellin, D.A.; Barry, D.T.; Sullivan, L.E.; Chawarski, M.C.; O'Connor, P.G.; Shottenfeld, R.S. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J. Gen. Intern. Med. 2007, 22, 527-530.
58. Minozzi, S.; Amato, L.; Vecchi, S.; Davoli, M.; Kirchmayer, U.; Verster, A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. 2006, doi: 10.1002/14651858.CD001333.pub2.
59. O'Connor, P.G.; Carroll, K.M.; Shi, J.M.; Schottenfeld, R.S.; Kosten, T.R.; Rounsaville, B.J. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann. Intern. Med. 1997, 127, 526-530.
60. Greenfield, S.F.; Shields, A.; Connery, H.S.; Livchits, V.; Yanov, S.A.; Lastimoso, C.S.; Strelis, A.K.; Mishustin, S.P.; Fitzmaurice, G.; Mathew, T.A.; Shin, S. Integrated management of physician-delivered alcohol care for tuberculosis patients: Design and implementation. Alcohol Clin. Exp. Res. 2010, 34, 317-330.
61. Sullivan, M. Improved Strategies for Outpatient Opioid Detoxification; NIH project number 1R01DA030484-01. National Institutes of Health: USA. Available online: http://projectreporter.nih.gov/project_info_description.cfm?aid=8027870&icde=10209146 (accessed on 8 October 2011).
62. Lucas, G.M.; Chaudhry, A.; Hsu, J.; Woodson, T.; Lau, B.; Olsen, Y.; Keruly, J.C.; Fiellin, D.A.; Finkelstein, R.; Barditch-Crovo, P.; et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann. Intern. Med. 2010, 152, 704-711.
63. Zaller, N.; Gillani, F.S.; Rich, J.D. A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness. AIDS Care 2007, 19, 1128-1133.
64. King, V.L.; Kidorf, M.S.; Stoller, K.B.; Schwartz, R.; Kolodner, K.; Brooner, R.K. A 12 month controlled trial of medical methadone maintenance integrated into an adaptive treatment model. J. Subst. Abuse Treat. 2006, 31, 385-393.
65. Baltimore Buprenorphine Initiative Newsletter. Baltimore Buprenorphine Initiative Updates, October 2008. Available online: http://www.bsasinc.org/media/doc/Baltimore%20buprenorphine%20initiativenewsletteroctober2008.pdf (accessed on 8 October 2011).
66. Drug Addiction Treatment Act of 2000. Public Law 106-310, 106th Congress, 2000. Government of United States: Washington, DC, USA. Available online: http://www.naabt.org/documents/DATA2000LAWTEXT.pdf (accessed on 8 October 2011).
67. Basu, S.; Smith-Rohrberg, D.; Bruce, R.D.; Altice, F.L. Models for integrating buprenorphine therapy into the primary HIV care setting. Clin. Infect. Dis. 2006, 42, 716-721.
68. Comer, S.D.; Sullivan, M.A.; Yu, E.; Rothenberg, J.L.; Kleber, H.D.; Kampman, K.; Dackis, C.; O'Brain, C.P. Injectable, sustained-release naltrexone for the treatment of opioid dependence. A randomized, placebo controlled trial. Arch. Gen. Psychiatry 2006, 63, 210-218.
69. Kunoe, N.; Lobmaier, P.; Vederhus, J.K.; Hjerkinn, B.; Hegstad, S.; Gossop, M.; Kristensen, O.; Waal, H. Retention in naltrexone implant treatment for opioid dependence. Drug Alcohol Depend. 2010, 111, 166-169
70. Davidson, L.; White, W. The concept of recovery as an organizing principle for integrating mental health and addiction services. J. Behav. Health Serv. Res. 2007, 34, 109-120.
71. Sowers, W. Transforming systems of care: The American Association of Community Psychiatrists guidelines for recovery oriented services. Community Ment. Health J. 2005, 41, 757-774.
72. White, W.L.; Mojer-Torres, L. Recovery-Oriented Methadone Maintenance; Great Lakes Addiction Technology Transfer Center, the Philadelphia Department of Behavioral Health and Mental Retardation Services, and the Northeast Addiction Technology Transfer Center: Detroit, MI, USA, 2010. Available online: http://www.ireta.org/resources/romm-exsum.pdf (accessed on 8 October 2011).
73. Ashcraft, L.; Anthony, W.A.; Martin, C. Home is where recovery begins. Behav. Healthc. 2008, 28, 13-15.
74. Jason, L.A.; Ferrari, J.R. Oxford House recovery homes: Characteristics and effectiveness. Psychol. Serv. 2010, 7, 92-102.